(RMD) ResMed Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(RMD) ResMed Inc. Bundle
Actionable Strategy Starts Here
This ResMed Inc. BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
AirSense 11 flagship CPAP
AirSense 11 is a Star for ResMed Inc.: it anchors the company’s biggest therapy area, with FY2025 revenue of about $5.1 billion across sleep and breathing care. Its connected features support recurring mask, tube, and filter replacement demand, while ResMed’s distribution reaches about 140 countries. That mix of scale, data connectivity, and repeat sales keeps AirSense 11 in a high-growth, high-share spot.
AirView cloud monitoring
AirView cloud monitoring sits at the center of ResMed’s remote therapy management, linking patients, clinicians, and devices in one workflow. ResMed’s FY2025 revenue was about US$5.1 billion, and this connected-care layer helps protect that base by making therapy follow-up easier and device switching less likely. In BCG terms, AirView acts like a growth engine in connected respiratory care.
myAir patient app
myAir supports adherence, education, and troubleshooting, so it helps ResMed keep sleep apnea patients active after the device sale. ResMed reported FY2025 revenue of $5.1 billion, and this app-backed model helps support that scale by extending the connected care ecosystem. It also raises long-term retention by keeping users engaged with therapy.
AirFit and AirTouch masks
AirFit and AirTouch sit in ResMed Inc.'s core mask franchise, where demand is sticky because cushions and masks wear out and are replaced on a regular cycle. In fiscal 2025, ResMed Inc. reported $5.1 billion in revenue, and masks/supplies stay one of the most recurring parts of that base. That keeps the line in a high-share, high-growth BCG position.
- Recurring replacement demand supports sales.
- Mask systems are a core franchise.
- Strong share keeps growth durable.
MatrixCare care management
MatrixCare is a strong Star because it serves senior living, skilled nursing, and hospice, three care settings where demand keeps rising as the 65+ population grows and providers digitize post-acute workflows. Its subscription software model supports recurring revenue, and that matters because ResMed can scale share without tying growth to one-off hardware sales.
- Targets high-need post-acute care.
- Benefits from aging demographics.
- Recurring subscriptions support expansion.
- Digitization lifts software adoption.
ResMed’s Connected Care Engines Power FY2025 Growth
ResMed Inc.’s Stars are its connected sleep and respiratory care engines: AirSense 11, AirView, myAir, and the AirFit/AirTouch mask family. In FY2025, ResMed Inc. reported about US$5.1 billion in revenue, backed by sales in about 140 countries. Their growth comes from connected use, repeat supply replacement, and high patient retention.
| Star | FY2025 signal | Why it fits |
|---|---|---|
| AirSense 11 | Core growth device | Drives therapy demand |
| AirView | Cloud workflow layer | Lowers switching |
| myAir | Adherence support | Lifts retention |
| AirFit/AirTouch | Recurring replacements | Sticky mask franchise |
What is included in the product
Detailed Word Document
ResMed’s BCG Matrix maps its sleep and respiratory units into Stars, Cash Cows, Question Marks, and Dogs.
Editable Excel File
Pain-point reliever: ResMed Inc. BCG Matrix puts each unit in one clean quadrant for fast strategic clarity.
Reference Sources
Provides a clear, credible source trail for ResMed Inc. that supports faster due diligence and more defensible decision-making.
Cash Cows
AirSense 10 installed base
AirSense 10 still anchors a huge installed base in sleep therapy, so replacement sales and accessories keep flowing with little new-customer spend. ResMed reported FY2025 revenue of $5.08 billion, and this mature platform helped support that cash generation. That is classic high-share cash cow behavior.
Brightree home care software
Brightree is ResMed Inc.'s mature HME, pharmacy, infusion, orthotics, and prosthetics software platform, so it fits the Cash Cow box. ResMed reported FY2025 revenue of $5.15 billion and gross margin of 58.5%, showing strong cash generation from recurring software and services. The market is steadier than newer digital care products, with Brightree acting as a dependable, lower-growth profit engine.
Astral ventilators
Astral ventilators fit ResMed Inc.’s Cash Cows: they serve chronic respiratory and home ventilation patients, where demand is steady and replacement-driven. ResMed Inc. reported FY2025 revenue of $5.09 billion and net income of $1.39 billion, showing strong cash generation from mature lines like Astral. The platform is established, so it supports dependable margins rather than fast growth.
AirCurve bilevel devices
AirCurve bilevel devices are a mature ResMed line with an established installed base, so they fit the Cash Cow role in the BCG matrix. ResMed’s FY2025 revenue was US$4.69 billion, and its Devices segment kept benefiting from repeat replacement demand rather than a new-market spike. The line serves a stable clinical need in bilevel therapy, which supports steady cash generation.
- Mature, replacement-driven demand
- Strong installed base
- Stable cash contributor
- FY2025 revenue: US$4.69 billion
Replacement masks and accessories
Replacement masks, headgear, and cushions are ResMed Inc.’s steady cash cow because patients replace them regularly, and they stay tied to the company’s installed device base. In FY2024, ResMed Inc. reported $4.69 billion in revenue, with recurring consumables helping support gross margin and cash flow even when device growth is slower.
Recurring replacement demand
Low growth, high stickiness
Light promo spend, steady cash
These sales are less cyclical than new device sales, so they keep revenue flowing with little extra marketing.
ResMed’s Cash Cows: Installed Base Turning Into Steady Profit
ResMed Inc.’s cash cows are its mature, replacement-led lines: AirSense 10, AirCurve, Astral, Brightree, and masks. In FY2025, ResMed Inc. posted US$5.08 billion revenue, 58.5% gross margin, and US$1.39 billion net income, showing how these low-growth businesses keep cash flowing from a large installed base.
| Cash cow | FY2025 signal |
|---|---|
| Devices and consumables | Installed base, repeat sales |
| Brightree | Recurring software revenue |
Get Your Copy
ResMed Inc. Reference Sources
The ResMed Inc. BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. No watermarks, no demo content—just the full, ready-to-use report. Download it instantly and use it for strategy, analysis, or presentations right away.
Dogs
HEALTHCAREfirst platform
HEALTHCAREfirst is a niche software asset inside ResMed Inc., serving home health and hospice agencies with EHR and billing tools. In a crowded post-acute software market, its share is likely modest, and slower category growth makes it fit the Dogs box in a BCG matrix. ResMed reported FY2025 revenue of about US$5.1 billion, but HEALTHCAREfirst does not appear to be a major growth driver.
Legacy diagnostic equipment
Legacy diagnostic equipment sits outside ResMed Inc.'s main connected-device growth engine; FY2025 revenue was about $5.1 billion, but the newer digital and cloud-linked lines drove the better mix. Demand is mostly replacement-led, so volume growth is slower than in connected therapy devices. That makes these products more exposed to price pressure and commoditization.
Older consumer sleep products
Older consumer sleep products are a small, non-core part of ResMed’s FY2025 $5.15 billion revenue base, which grew 10% year over year. They face weaker brand pull than the company’s prescription PAP and mask franchises, so share stays low and growth is thin. That makes them fit the "dog" box in the BCG Matrix.
Older connectivity modules
Older connectivity modules fit the Dogs bucket because they support legacy installs, but newer cloud-first workflows have taken the growth lead. In FY2025, ResMed kept scaling its connected ecosystem, yet these older units added little strategic lift and mainly protected service continuity.
- Legacy hardware: operational, not growth-led
- Cloud workflows now drive the value pool
- Thin strategic value versus newer platforms
Small regional accessory lines
ResMed Inc. posted FY2025 revenue of US$5.08 billion, so small regional accessory lines sit far below the global core franchise in scale. These lines can still absorb sales, logistics, and regulatory support without building meaningful share, which fits classic dog territory in a BCG Matrix. If growth stays weak and share stays thin, capital is better used on core masks and devices.
- Low scale versus US$5.08B core
- Support cost can outrun share gains
ResMed’s Dog Assets: Low Growth, Low Lift, Capital Drains
Dogs in ResMed Inc.'s BCG Matrix are small, slow-growth legacy lines like HEALTHCAREfirst, older diagnostic gear, and older connectivity modules. They sit far from the FY2025 revenue base of about US$5.08 billion to US$5.15 billion, so they add limited strategic lift and face price pressure. Capital is better used on core masks, PAP devices, and cloud-linked workflows.
| Dog asset | FY2025 view | BCG signal |
|---|---|---|
| HEALTHCAREfirst | Niche, low share | Dog |
| Legacy diagnostics | Replacement-led demand | Dog |
| Older connectivity modules | Low strategic lift | Dog |
Question Marks
Propeller solutions
Propeller solutions sits in a question mark bucket: it targets digital respiratory management for asthma and related chronic care, a large market, but ResMed does not lead it the way it does PAP and masks. The platform was built for connected inhaler and symptom tracking, but share gains are still unproven. That makes it a growth bet, not a cash engine, with adoption tied to payer and provider uptake.
U-Sleep compliance tracking
U-Sleep is still a Question Mark: it targets home medical equipment compliance workflows, and that market is growing as obstructive sleep apnea affects about 1 billion adults worldwide. But it must beat entrenched workflow software and prove it can scale beyond a niche use case.
That means ResMed Inc. likely needs more investment in product, sales, and integration to turn U-Sleep into a leader. Without faster adoption and clear economics, it stays a low-share, high-upside bet.
Dental devices
Dental devices fit ResMed Inc.’s Question Mark bucket: oral appliance therapy is tied to the fast-growing sleep-apnea market, but it is not a core share leader for the Company. ResMed reported FY2025 revenue of about $5.2 billion, yet it does not break out dental devices as a major standalone line, which signals limited current scale. If adoption rises in the oral-appliance segment, this could turn into a stronger growth option, but today it still lacks clear dominance.
AI analytics add-ons
ResMed Inc. AI analytics add-ons sit in the Question Marks quadrant: they can sharpen clinical insight, improve adherence, and cut service time, but their monetization is still early. In FY2025, ResMed Inc. posted about $5.1 billion in revenue, showing strong scale, yet these add-ons have not clearly turned into major profit drivers.
The market for AI in respiratory and sleep care is growing fast, but share and pricing power are still forming. That makes these tools promising, but not yet proven stars in the BCG Matrix.
- AI lifts insight and efficiency.
- FY2025 revenue: about $5.1 billion.
- Growth is real; monetization is not.
- Still a Question Mark, not a Star.
International SaaS expansion
ResMed Inc.’s international SaaS push is a question mark: FY2025 revenue was about $5.1 billion, but SaaS growth outside North America still depends on local rules, payer ties, and channel execution. The upside is clear, yet share gains stay limited until scale and repeatable go-to-market reach land.
- FY2025 revenue: about $5.1 billion
- Growth outside North America needs local fit
- Scale must come before strong share gains
ResMed’s Question Marks: Early Growth Bets With Big Upside
ResMed Inc.’s Question Marks are growth bets with low current share, including Propeller, U-Sleep, dental devices, AI add-ons, and international SaaS. FY2025 revenue was about $5.1 billion, but these units are still early in monetization and scale. They could move up only if adoption, payer fit, and integration improve fast.
| Area | Status | Key point |
|---|---|---|
| Propeller | Question Mark | Growth market, unproven share |
| U-Sleep | Question Mark | Needs wider workflow adoption |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.